Lung Cancer Clinical Trials

Showing 1321-1340 of 3,692 trials

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

NCT05878964

The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps. In the first one, it will be investigated the relationship between the skin toxicity related to the use selected therapies and the quality of life of patients already receiving these therapies for treatment of their cancer. In the second one, it will be evaluated the relationship between skin toxicity and quality of life over three months of treatment in patients initially naïve for selected therapies. Cancer included in the analysis are NSCLC, renal cancer, gastric cancer, breast cancer, bladder cancer, melanoma, squamous cell carcinoma of the head and neck.

Lung CancerBreast CancerKidney Cancer+5 more

Fondazione Policlinico Universitario Agostino Gemelli IRCCS420 participantsStarted May 2023

Roma, Italy

RECRUITING

CMR Right Ventricular Contractile Reserve Following Lung Resection

NCT06465277

Feasibility study investigating CMR dobutamine stress testing before and after lung resection

Lung CancerSurgeryAnesthesia

Belfast Health and Social Care Trust42 participantsStarted Jul 2023

Belfast, Northern Ireland, United Kingdom

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

CMR Right Ventricular Contractile Reserve Following Lung Resection

Related Searches

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors

PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

Descriptive Observational Study ALK-2016-CPHG

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

A Study of KF-0210 in Advanced Solid Tumors Patients

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients